Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.H Lundbeck, Denmark-based developer, manufacturer and marketer of pharmaceuticals for the treatment of diseases of the central nervous system (CNS), has paid £0.3m research milestone under its drug discovery agreement with Vernalis.
Subscribe to our email newsletter
Under the contract, the companies will use Vernalis’ fragment and structure-based drug discovery platform against LRRK2.
As per the terms of the deal, Vernalis is entitled to receive fees and a potential share in the downstream success of the product in the form of milestones and royalties on sales.
Vernalis CEO Ian Garland said achieving this milestone further validates the strength of their fragment and structure-based drug discovery platforms.